Evidence map›Paper›PMID 34755110›Full record

ArticleBrain communications2021

Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach.

Tianrong Yeo, Fay Probert, Megan Sealey, Luisa Saldana, Ruth Geraldes, Sebastian Höeckner, Eric Schiffer, Timothy D W Claridge, David Leppert, Gabriele DeLuca and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. PlasmaNeurology(R) neuroimmunology & neuroinflammation · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Current and Future Biomarkers in Multiple Sclerosis.International journal of molecular sciences · 2022
    Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Tianrong YeoDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.ORCID https://orcid.org/0000-0002-3648-0953
Fay ProbertDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.ORCID https://orcid.org/0000-0002-8580-2023
Megan SealeyDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.
Luisa SaldanaNuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.
Ruth GeraldesNuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.
Sebastian Höecknernumares AG, Regensburg 93053, Germany.
Eric Schiffernumares AG, Regensburg 93053, Germany.
Timothy D W ClaridgeChemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford OX1 3TA, UK.
David LeppertNeurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital Basel and University of Basel, Basel CH-4031, Switzerland.
Gabriele DeLucaNuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.
Jens KuhleNeurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital Basel and University of Basel, Basel CH-4031, Switzerland.ORCID https://orcid.org/0000-0002-3713-9570
Jacqueline PalaceNuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.
Daniel C AnthonyDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.

Funding

Medical Research Council MC_PC_15029
6 · The paper itself

Abstract

Accurate determination of relapses in multiple sclerosis is important for diagnosis, classification of clinical course and therapeutic decision making. The identification of biofluid markers for multiple sclerosis relapses would add to our current diagnostic armamentarium and increase our understanding of the biology underlying the clinical expression of inflammation in multiple sclerosis. However, there is presently no biofluid marker capable of objectively determining multiple sclerosis relapses although some, in particular neurofilament-light chain, have shown promise. In this study, we sought to determine if metabolic perturbations are present during multiple sclerosis relapses, and, if so, identify candidate metabolite biomarkers and evaluate their discriminatory abilities at both group and individual levels, in comparison with neurofilament-light chain. High-resolution global and targeted

Indexed as

biomarkermetabolitesmetabolomicsmultiple sclerosisrelapse

Identifiers

PMID34755110
PMCPMC8568847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.